Genzyme, a Sanofi company, received a six-month Priority Review designation from the FDA for its NDA for Cerdelga, an investigational oral therapy for adult patients with Gaucher disease type 1. Genzyme is developing eliglustat, a capsule to be taken twice daily, to provide an effective oral treatment alternative for adult patients with Gaucher disease type 1, and to provide a broader range of treatment options for Gaucher patients and physicians. Genzyme’s clinical development program for elig...